Page 90 - Read Online

Bongiovanni et al. J Cancer Metastasis Treat 2022;8:44 https://dx.doi.org/10.20517/2394-4722.2022.78 Page 11 of 12

93. DOI PubMed PMC
27. Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1):
an open-label, non-randomised, phase 2 study. Lancet Respir Med 2018;6:451-60. DOI PubMed
28. Calabrò L, Rossi G, Morra A, et al. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a
follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir Med 2021;9:969-76. DOI PubMed
29. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural
mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol
2019;20:239-53. DOI PubMed
30. Disselhorst MJ, Quispel-janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural
mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 2019;7:260-70. DOI PubMed
31. Scherpereel A, Antonia S, Bautista Y, et al. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of
unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer 2022;167:8-16. DOI
PubMed
32. Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable
malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 2022;33:488-99. DOI PubMed
33. Wright K. FDA approves nivolumab plus ipilimumab for previously untreated unresectable malignant pleural mesothelioma. Oncology
2020;34:502-3. DOI PubMed
34. Kaur J, Elms J, Munn AL, Good D, Wei MQ. Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in
combination therapy. Crit Rev Oncol Hematol 2021;164:103417. DOI PubMed
35. Albittar AA, Alhalabi O, Glitza Oliva IC. Immunotherapy for melanoma. Adv Exp Med Biol 2020;1244:51-68. DOI
36. Esposito G, Palumbo G, Carillio G, et al. Immunotherapy in small cell lung cancer. Cancers 2020;12:2522. DOI PubMed PMC
37. Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol
Hepatol 2019;16:361-75. DOI PubMed PMC
38. Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA 2020;324:1980-91. DOI PubMed
39. Forde PM, Anagnostou V, Sun Z, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival,
genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med 2021;27:1910-20. DOI PubMed PMC
40. Nowak AK, Lesterhuis WJ, Kok P, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural
mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol 2020;21:1213-23. DOI PubMed
41. Kok PS, Forde PM, Hughes B, et al. Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced
pleural Mesothelioma-a phase 3 randomised trial. BMJ Open 2022;12:e057663. DOI PubMed PMC
42. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192-7. DOI PubMed
43. Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor
activity in solid malignancies. Cancer Immunol Res 2014;;2:112-20. DOI PubMed PMC
44. Wang X, Rivière I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 2016;3:16015.
DOI PubMed PMC
45. Maus MV, Haas AR, Beatty GL, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer
Immunol Res 2013;1:26-31. PubMed PMC
46. Haas AR, Tanyi JL, O’Hara MH, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing
mesothelin in advanced solid cancers. Mol Ther 2019;27:1919-29. DOI PubMed PMC
47. Ghosn M, Cheema W, Zhu A, et al. Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for
pleural malignancies in a phase I/II clinical trial. Lung Cancer 2022;165:1-9. DOI PubMed PMC
48. Adusumilli PS, Zauderer MG, Riviere I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with
malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov 2021;11:2768. DOI PubMed
PMC
49. Schuberth PC, Hagedorn C, Jensen SM, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-
directed T cells. J Transl Med 2013;11:187. DOI PubMed PMC
50. Petrausch U, Schuberth PC, Hagedorn C, et al. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive
malignant pleural mesothelioma (FAPME-1). BMC Cancer 2012;12:615. DOI PubMed PMC
51. Curioni A, Britschgi C, Hiltbrunner S, et al. A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered
autologous anti-FAP-targeted CAR T-cells. Ann Oncol 2019;30:v501. DOI
52. Thayaparan T, Petrovic RM, Achkova DY, et al. CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.
OncoImmunology 2017;6:e1363137. DOI PubMed PMC
53. Klampatsa A, Achkova DY, Davies DM, et al. Intracavitary “T4 immunotherapy” of malignant mesothelioma using pan-ErbB re-
targeted CAR T-cells. Cancer Lett 2017;393:52-9. DOI PubMed
54. Al-Taei S, Salimu J, Lester JF, et al. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural
mesothelioma. Lung Cancer 2012;77:312-8. DOI PubMed
55. Beard RE, Zheng Z, Lagisetty KH, et al. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in
several different cancer histologies and cancer stem cells. J Immunother Cancer 2014;2:25. DOI PubMed PMC
56. Akbari P, Huijbers EJM, Themeli M, Griffioen AW, van Beijnum JR. The tumor vasculature an attractive CAR T cell target in solid